Skip to main content
Top
Published in: Journal of Translational Medicine 1/2012

Open Access 01-09-2012 | Proceedings

An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma

Authors: Mariko Masuda, Yasuhiro Miki, Shuko Hata, Kiyoshi Takagi, Minako Sakurai, Katsuhiko Ono, Koyu Suzuki, Yang Yang, Eriko Abe, Hisashi Hirakawa, Takanori Ishida, Takashi Suzuki, Noriaki Ohuchi, Hironobu Sasano

Published in: Journal of Translational Medicine | Special Issue 1/2012

Login to get access

Abstract

Background

Estrogen plays an important role in the development of estrogen-dependent breast carcinoma. Recently, several studies demonstrated a possible involvement of several micro RNAs (miRNAs) in the development of resistance to endocrine therapy in breast cancer patients, but the correlation between estrogen actions and miRNA expression in breast carcinoma still remains largely unknown. Therefore, in this study, we examined the in vitro effects of estrogen upon miRNA expression profiles in breast carcinoma.

Methods

We first screened the miRNA expression profiles induced by 17β-Estradiol (E2) using RT2 miRNA PCR Array in the ER-positive breast carcinoma cell line MCF-7. We identified miR-7 as the important miRNA associated with estrogen actions in these cells and further examined the changes of estrogen-dependent EGFR expression by miR-7 in ER-positive or -negative breast carcinoma cell lines including MCF-7. We also evaluated the correlation between miR-7 and EGFR expression in breast carcinoma cells derived from 21 patients using laser capture microdissection combined with quantitative reverse transcriptase-PCR.

Results

Seventeen miRNAs were significantly induced by E2 treatment in the MCF-7 cell line. Among 17 miRNAs induced by estradiol treatment, only miR-7 expression was significantly decreased by subsequent ICI treatment. The expression of miR-7 was up-regulated 2.94-fold by E2 treatment. miR-7 was reported to suppress epidermal growth factor receptor (EGFR) expression in several human malignancies. Transfection of miR-7 significantly suppressed EGFR mRNA levels in MCF-7 cells. Depletion of E2 from cell culture media also increased the expression level of EGFR mRNA in MCF-7 and T-47D cells but not in ER-negative, MDA-MB-231 and SK-BR-3 cells. We also evaluated the status of miR-7 in breast carcinoma tissues, but the correlation between the status of miR-7 and EGFR in carcinoma cells isolated by laser capture microscopy was not detected.

Conclusions

These results suggest that miR-7 may play a role in the development of resistance to endocrine therapy in breast cancer patients through regulating EGFR expression of carcinoma cells.
Literature
1.
go back to reference Miyoshi Y, Murase K, Saito M, Oh K: Prediction of hormone sensitivity for breast cancers. Breast Cancer. 2010, 17 (2): 86-91. 10.1007/s12282-009-0177-x.CrossRefPubMed Miyoshi Y, Murase K, Saito M, Oh K: Prediction of hormone sensitivity for breast cancers. Breast Cancer. 2010, 17 (2): 86-91. 10.1007/s12282-009-0177-x.CrossRefPubMed
2.
go back to reference Massarweh S, Schiff R: Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer. 2006, 13 (Suppl 1): S15-24.CrossRefPubMed Massarweh S, Schiff R: Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer. 2006, 13 (Suppl 1): S15-24.CrossRefPubMed
3.
go back to reference Ambros V: microRNAs: tiny regulators with great potential. Cell. 2001, 107 (7): 823-826. 10.1016/S0092-8674(01)00616-X.CrossRefPubMed Ambros V: microRNAs: tiny regulators with great potential. Cell. 2001, 107 (7): 823-826. 10.1016/S0092-8674(01)00616-X.CrossRefPubMed
4.
5.
go back to reference Leung AK, Sharp PA: microRNAs: a safeguard against turmoil?. Cell. 2007, 130 (4): 581-585. 10.1016/j.cell.2007.08.010.CrossRefPubMed Leung AK, Sharp PA: microRNAs: a safeguard against turmoil?. Cell. 2007, 130 (4): 581-585. 10.1016/j.cell.2007.08.010.CrossRefPubMed
6.
go back to reference Zhang B, Pan X, Cobb GP, Anderson TA: microRNA as oncogenes and tumor suppressors. Dev Biol. 2007, 302: 1-12. 10.1016/j.ydbio.2006.08.028.CrossRefPubMed Zhang B, Pan X, Cobb GP, Anderson TA: microRNA as oncogenes and tumor suppressors. Dev Biol. 2007, 302: 1-12. 10.1016/j.ydbio.2006.08.028.CrossRefPubMed
7.
go back to reference Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65 (16): 7065-7070. 10.1158/0008-5472.CAN-05-1783.CrossRefPubMed Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65 (16): 7065-7070. 10.1158/0008-5472.CAN-05-1783.CrossRefPubMed
8.
go back to reference Adams BD, Furneaux H, White BA: The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol. 2007, 21: 1132-1147. 10.1210/me.2007-0022.CrossRefPubMed Adams BD, Furneaux H, White BA: The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol. 2007, 21: 1132-1147. 10.1210/me.2007-0022.CrossRefPubMed
9.
go back to reference Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ: MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 2008, 283 (45): 31079-31086. 10.1074/jbc.M806041200.PubMedCentralCrossRefPubMed Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ: MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 2008, 283 (45): 31079-31086. 10.1074/jbc.M806041200.PubMedCentralCrossRefPubMed
10.
go back to reference Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP: MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 2011, 30 (9): 1082-1097. 10.1038/onc.2010.487.PubMedCentralCrossRefPubMed Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP: MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 2011, 30 (9): 1082-1097. 10.1038/onc.2010.487.PubMedCentralCrossRefPubMed
11.
go back to reference Maillot G, Lacroix-Triki M, Pierredon S, Gratadou L, Schmidt S, Bénès V, Roché H, Dalenc F, Auboeuf D, Millevoi S, Vagner S: Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Res. 2009, 69 (21): 8332-8340. 10.1158/0008-5472.CAN-09-2206.CrossRefPubMed Maillot G, Lacroix-Triki M, Pierredon S, Gratadou L, Schmidt S, Bénès V, Roché H, Dalenc F, Auboeuf D, Millevoi S, Vagner S: Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Res. 2009, 69 (21): 8332-8340. 10.1158/0008-5472.CAN-09-2206.CrossRefPubMed
12.
go back to reference Bhat-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, Carroll JS, Brown M, Hammond S, Srour EF, Liu Y, Nakshatri H: Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res. 2009, 37 (14): 4850-4861. 10.1093/nar/gkp500.PubMedCentralCrossRefPubMed Bhat-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, Carroll JS, Brown M, Hammond S, Srour EF, Liu Y, Nakshatri H: Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res. 2009, 37 (14): 4850-4861. 10.1093/nar/gkp500.PubMedCentralCrossRefPubMed
13.
go back to reference Toloubeydokhti T, Pan Q, Luo X, Bukulmez O, Chegini N: The expression and ovarian steroid regulation of endometrial micro-RNAs. Reprod Sci. 2008, 15 (10): 993-1001. 10.1177/1933719108324132.PubMedCentralCrossRefPubMed Toloubeydokhti T, Pan Q, Luo X, Bukulmez O, Chegini N: The expression and ovarian steroid regulation of endometrial micro-RNAs. Reprod Sci. 2008, 15 (10): 993-1001. 10.1177/1933719108324132.PubMedCentralCrossRefPubMed
14.
go back to reference Pan Q, Luo X, Chegini N: Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol Med. 2008, 12 (1): 227-240.PubMedCentralCrossRefPubMed Pan Q, Luo X, Chegini N: Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol Med. 2008, 12 (1): 227-240.PubMedCentralCrossRefPubMed
15.
go back to reference Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP: MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 2011, 30 (9): 1082-1097. 10.1038/onc.2010.487.PubMedCentralCrossRefPubMed Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP: MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 2011, 30 (9): 1082-1097. 10.1038/onc.2010.487.PubMedCentralCrossRefPubMed
16.
go back to reference Okamura K, Hagen JW, Duan H, Tyler DM, Lai EC: The mirtron pathway generates microRNA-class regulatory RNAs in Drosophila. Cell. 2007, 130 (1): 89-100. 10.1016/j.cell.2007.06.028.PubMedCentralCrossRefPubMed Okamura K, Hagen JW, Duan H, Tyler DM, Lai EC: The mirtron pathway generates microRNA-class regulatory RNAs in Drosophila. Cell. 2007, 130 (1): 89-100. 10.1016/j.cell.2007.06.028.PubMedCentralCrossRefPubMed
17.
go back to reference Kim VN, Nam JW: Genomics of microRNA. Trends Genet. 2006, 22 (3): 165-173. 10.1016/j.tig.2006.01.003.CrossRefPubMed Kim VN, Nam JW: Genomics of microRNA. Trends Genet. 2006, 22 (3): 165-173. 10.1016/j.tig.2006.01.003.CrossRefPubMed
18.
go back to reference Nagai MA, Da Rós N, Neto MM, de Faria Junior SR, Brentani MM, Hirata R, Neves EJ: Gene expression profiles in breast tumors regarding the presence or absence of estrogen and progesterone receptors. Int J Cancer. 2004, 111 (6): 892-899. 10.1002/ijc.20329.CrossRefPubMed Nagai MA, Da Rós N, Neto MM, de Faria Junior SR, Brentani MM, Hirata R, Neves EJ: Gene expression profiles in breast tumors regarding the presence or absence of estrogen and progesterone receptors. Int J Cancer. 2004, 111 (6): 892-899. 10.1002/ijc.20329.CrossRefPubMed
19.
go back to reference Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S, Purow B: microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008, 68 (10): 3566-3572. 10.1158/0008-5472.CAN-07-6639.CrossRefPubMed Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S, Purow B: microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008, 68 (10): 3566-3572. 10.1158/0008-5472.CAN-07-6639.CrossRefPubMed
20.
go back to reference Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ: Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem. 2009, 284 (9): 5731-5741.CrossRefPubMed Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ: Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem. 2009, 284 (9): 5731-5741.CrossRefPubMed
21.
go back to reference Giles KM, Barker A, Zhang PM, Epis MR, Leedman PJ: MicroRNA regulation of growth factor receptor signaling in human cancer cells. Methods Mol Biol. 2011, 676: 147-163. 10.1007/978-1-60761-863-8_11.CrossRefPubMed Giles KM, Barker A, Zhang PM, Epis MR, Leedman PJ: MicroRNA regulation of growth factor receptor signaling in human cancer cells. Methods Mol Biol. 2011, 676: 147-163. 10.1007/978-1-60761-863-8_11.CrossRefPubMed
22.
23.
go back to reference Polychronis A, Sinnett HD, Hadjiminas D, Singhal H, Mansi JL, Shivapatham D, Shousha S, Jiang J, Peston D, Barrett N, Vigushin D, Morrison K, Beresford E, Ali S, Slade MJ, Coombes RC: Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol. 2005, 6 (6): 383-391. 10.1016/S1470-2045(05)70176-5.CrossRefPubMed Polychronis A, Sinnett HD, Hadjiminas D, Singhal H, Mansi JL, Shivapatham D, Shousha S, Jiang J, Peston D, Barrett N, Vigushin D, Morrison K, Beresford E, Ali S, Slade MJ, Coombes RC: Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol. 2005, 6 (6): 383-391. 10.1016/S1470-2045(05)70176-5.CrossRefPubMed
24.
go back to reference Massarweh S, Tham YL, Huang J, Sexton K, Weiss H, Tsimelzon A, Beyer A, Rimawi M, Cai WY, Hilsenbeck S, Fuqua S, Elledge R: A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011, 129 (3): 819-827. 10.1007/s10549-011-1679-8.PubMedCentralCrossRefPubMed Massarweh S, Tham YL, Huang J, Sexton K, Weiss H, Tsimelzon A, Beyer A, Rimawi M, Cai WY, Hilsenbeck S, Fuqua S, Elledge R: A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011, 129 (3): 819-827. 10.1007/s10549-011-1679-8.PubMedCentralCrossRefPubMed
25.
go back to reference Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J, Clark E, Magill P, Dowsett M: A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 2007, 25 (25): 3816-3822. 10.1200/JCO.2006.09.6578.CrossRefPubMed Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J, Clark E, Magill P, Dowsett M: A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 2007, 25 (25): 3816-3822. 10.1200/JCO.2006.09.6578.CrossRefPubMed
26.
go back to reference Green MD, Francis PA, Gebski V, Harvey V, Karapetis C, Chan A, Snyder R, Fong A, Basser R, Forbes JF: Australian New Zealand Breast Cancer Trials Group. Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Ann Oncol. 2009, 20 (11): 1813-1817. 10.1093/annonc/mdp202.CrossRefPubMed Green MD, Francis PA, Gebski V, Harvey V, Karapetis C, Chan A, Snyder R, Fong A, Basser R, Forbes JF: Australian New Zealand Breast Cancer Trials Group. Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Ann Oncol. 2009, 20 (11): 1813-1817. 10.1093/annonc/mdp202.CrossRefPubMed
27.
go back to reference Jiang L, Liu X, Chen Z, Jin Y, 10Heidbreder CE, Kolokythas A, Wang A, Dai Y, Zhou X: MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J. 2010, 432 (1): 199-205. 10.1042/BJ20100859.PubMedCentralCrossRefPubMed Jiang L, Liu X, Chen Z, Jin Y, 10Heidbreder CE, Kolokythas A, Wang A, Dai Y, Zhou X: MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J. 2010, 432 (1): 199-205. 10.1042/BJ20100859.PubMedCentralCrossRefPubMed
28.
go back to reference Clarke RB, Howell A, Anderson E: Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br J Cancer. 1997, 75: 251-257. 10.1038/bjc.1997.41.PubMedCentralCrossRefPubMed Clarke RB, Howell A, Anderson E: Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br J Cancer. 1997, 75: 251-257. 10.1038/bjc.1997.41.PubMedCentralCrossRefPubMed
29.
go back to reference Molloy CA, May FE, Westley BR: Insulin receptor substrate 1 expression is regulated by oestrogen in the MCF-7 human breast cancer cell line. J Biol Chem. 2000, 275: 12565-12571. 10.1074/jbc.275.17.12565.CrossRefPubMed Molloy CA, May FE, Westley BR: Insulin receptor substrate 1 expression is regulated by oestrogen in the MCF-7 human breast cancer cell line. J Biol Chem. 2000, 275: 12565-12571. 10.1074/jbc.275.17.12565.CrossRefPubMed
30.
go back to reference Yee D, Lee AV: Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia. 2000, 5: 107-115. 10.1023/A:1009575518338.CrossRefPubMed Yee D, Lee AV: Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia. 2000, 5: 107-115. 10.1023/A:1009575518338.CrossRefPubMed
31.
go back to reference Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D: Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999, 13: 787-796. 10.1210/me.13.5.787.CrossRefPubMed Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D: Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999, 13: 787-796. 10.1210/me.13.5.787.CrossRefPubMed
32.
go back to reference Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjørn B, Dowsett M, Einstein , Lønning P: Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res. 2001, 7 (5): 1230-1236.PubMed Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjørn B, Dowsett M, Einstein , Lønning P: Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res. 2001, 7 (5): 1230-1236.PubMed
Metadata
Title
An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma
Authors
Mariko Masuda
Yasuhiro Miki
Shuko Hata
Kiyoshi Takagi
Minako Sakurai
Katsuhiko Ono
Koyu Suzuki
Yang Yang
Eriko Abe
Hisashi Hirakawa
Takanori Ishida
Takashi Suzuki
Noriaki Ohuchi
Hironobu Sasano
Publication date
01-09-2012
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue Special Issue 1/2012
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-10-S1-S2

Other articles of this Special Issue 1/2012

Journal of Translational Medicine 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine